Trial Profile
A randomized open-label blinded prospective study designed to compare the efficacy and safety between once-weekly and daily administration of alendronate in patients with corticosteroid-induced osteoporosis
Status:
Discontinued
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 24 Sep 2011
Price :
$35
*
At a glance
- Drugs Alendronic acid (Primary)
- Indications Corticosteroid-induced osteoporosis
- Focus Therapeutic Use
- 24 Sep 2011 New trial record